Press Release for the quarter and year March 31, 2026
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Viyash Scientific reported its strongest quarter ever in Q4 FY26 with revenues of Rs 9,200 million, up 19.1% year-over-year. EBITDA surged 63.8% to Rs 2,001 million, crossing the Rs 2,000 million mark for the first time. Full-year FY26 revenues reached Rs 34,203 million with 13.8% growth, while EBITDA jumped 59.6% to Rs 7,025 million. Profitability saw dramatic improvement with PAT of Rs 2,246 million, up 1,324% from Rs 158 million in FY25. The company attributed results to successful integration of facilities and merger synergies. The balance sheet is strong with Net Debt/EBITDA at just 0.2x. Management mentioned they are actively evaluating selective inorganic opportunities to strengthen the platform.
The company delivered exceptional growth driven by merger synergies and operating leverage. The strong deleveraged balance sheet and mention of acquisition plans signals management is positioning for further consolidation. The stock appears fundamentally strong with margin expansion from 14.6% to 20.5%.